Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus
- 1 August 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cellular & Molecular Immunology
- Vol. 18 (8), 1896-1903
- https://doi.org/10.1038/s41423-020-0472-1
Abstract
Dysregulated B-cell activation plays pivotal roles in systemic lupus erythematosus (SLE), which makes B-cell depletion a potential strategy for SLE treatment. The clinical success of anti-CD19 CAR-T cells in treating B-cell malignancies has attracted the attention of researchers. In this study, we aimed to investigate the feasibility of applying anti-CD19 CAR-T cell therapy to SLE treatment in a mouse disease model. We constructed murine anti-CD19 CARs with either CD28 or 4-1BB as the intracellular costimulatory motif and evaluated the therapeutic function of the corresponding CAR-T cells by infusing them into MRL-lpr mice. Furthermore, anti-CD19 CAR-T cells were transferred to MRL-lpr mice before the onset of disease to determine their role in SLE prevention. According to our observations, compared with antibody treatment, the adoptive transfer of our anti-CD19 CAR-T cells showed a more sustained B-cell-depletion effect in MRL-lpr mice. The transfer of syngeneic anti-CD19 CAR-T cells not only prevented disease pathogenesis before the onset of disease symptoms but also displayed therapeutic benefits at a later stage after disease progression. We also tried to optimize the treatment strategy and found that compared with CAR-T cells with the CD28 costimulatory motif, CAR-T cells with the 4-1BB costimulatory motif showed better therapeutic efficiency without cell enrichment. Taken together, these results show that anti-CD19 CAR-T cell therapy was effective in the prevention and treatment of a murine model of SLE, indicating its potential for clinical use in patients.Funding Information
- National Natural Science Foundation of China (31530019, 31770954, 31900628)
- Fundamental Research Funds for the Central Universities
This publication has 31 references indexed in Scilit:
- B-cell depletion in the treatment of lupus nephritisNature Reviews Nephrology, 2012
- CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal deliveryJournal of Neuroinflammation, 2012
- Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunityArthritis Research & Therapy, 2012
- B cell biomarkers of rituximab responses in systemic lupus erythematosusArthritis & Rheumatism, 2011
- Rituximab-treated membranous lupus nephritis: clinical outcome and effects on electron dense depositsAnnals Of The Rheumatic Diseases, 2011
- Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cellsBlood, 2010
- Natural Expression of the CD19 Antigen Impacts the Long-Term Engraftment but Not Antitumor Activity of CD19-Specific Engineered T CellsThe Journal of Immunology, 2010
- Systemic Lupus ErythematosusThe New England Journal of Medicine, 2008
- Development of Autoantibodies before the Clinical Onset of Systemic Lupus ErythematosusThe New England Journal of Medicine, 2003
- Targeting autoantigen-specific T cells and suppression of autoimmune encephalomyelitis with receptor-modified T lymphocytesNature Biotechnology, 2002